A phase 1 dose-escalation and expansion-cohort study of the oral CDK7 inhibitor XL102 as a single-agent and in combination therapy in patients (pts) with advanced solid tumors

被引：0
|
作者：
Shapiro, Geoffrey
Barve, Minal A.
Bhave, Manali A.
Subbiah, Vivek
Uttamsingh, Shailaja
Sharma, Keerti
Andrianova, Lana
Patnaik, Amita
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Mary Crowley Canc Res, Dallas, TX USA
[3] Emory Univ, Sch Med, Atlanta, GA USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA
[5] Exelixis Inc, Alameda, CA USA
[6] START, San Antonio, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3176
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
    Jeffrey R. Infante
    Roger B. Cohen
    Kevin B. Kim
    Howard A. Burris
    Gregory Curt
    Ugochi Emeribe
    Delyth Clemett
    Helen K. Tomkinson
    Patricia M. LoRusso
    Investigational New Drugs, 2017, 35 : 576 - 588
  • [32] Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors
    Lockhart, A. Craig
    Sundaram, Shankar
    Sarantopoulos, John
    Mita, Monica M.
    Wang-Gillam, Andrea
    Moseley, Jennifer L.
    Barber, Stephanie L.
    Lane, Alex R.
    Wack, Claudine
    Kassalow, Laurent
    Dedieu, Jean-Francois
    Mita, Alain C.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (06) : 1236 - 1245
  • [33] A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas
    Infante, Jeffrey R.
    Shapiro, Geoffrey
    Witteveen, Petronella
    Gerecitano, John F.
    Ribrag, Vincent
    Chugh, Rashmi
    Issa, Isra
    Chakraborty, Abhijit
    Matano, Alessandro
    Zhao, Xumei
    Parasuraman, Sudha
    Cassier, Phillipe
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors
    Isambert, Nicolas
    Freyer, Gilles
    Zanetta, Sylvie
    You, Benoit
    Fumoleau, Pierre
    Falandry, Claire
    Favier, Laure
    Assadourian, Sylvie
    Soussan-Lazard, Karen
    Ziti-Ljajic, Samira
    Trillet-Lenoir, Veronique
    CLINICAL CANCER RESEARCH, 2012, 18 (06) : 1743 - 1750
  • [35] A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
    Infante, Jeffrey R.
    Cohen, Roger B.
    Kim, Kevin B.
    Burris, Howard A., III
    Curt, Gregory
    Emeribe, Ugochi
    Clemett, Delyth
    Tomkinson, Helen K.
    LoRusso, Patricia M.
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (05) : 576 - 588
  • [36] A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
    LoRusso, Patricia M.
    Infante, Jeffrey R.
    Kim, Kevin B.
    Burris, Howard A., III
    Curt, Gregory
    Emeribe, Ugochi
    Clemett, Delyth
    Tomkinson, Helen K.
    Cohen, Roger B.
    BMC CANCER, 2017, 17
  • [37] A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with docetaxel in patients with advanced solid tumors
    Robert, F.
    Sandler, A.
    Schiller, J. H.
    Ilagan, J.
    Harper, K.
    Vermeulen, W.
    Liu, G.
    Tye, L.
    Chao, R.
    Verkh, L.
    Traynor, A.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3514S - 3515S
  • [38] A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
    Patricia M. LoRusso
    Jeffrey R. Infante
    Kevin B. Kim
    Howard A. Burris
    Gregory Curt
    Ugochi Emeribe
    Delyth Clemett
    Helen K. Tomkinson
    Roger B. Cohen
    BMC Cancer, 17
  • [39] Phase 1, first-in-human, dose-escalation study of oral TP-1287, a cyclin dependent kinase 9 (CDK9) inhibitor, in patients (pts) with advanced solid tumors (ASTs).
    Vogelzang, Nicholas J.
    George, Ben
    Ashenbramer, Nissa
    Edenfield, William J.
    Richards, Donald
    Gross, Mitchell E.
    Fine, Gil D.
    Martinez, Pablo
    CANCER RESEARCH, 2022, 82 (12)
  • [40] A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors
    Patnaik, Amita
    Hamilton, Erika
    Xing, Yan
    Rasco, Drew W.
    Smith, Lon
    Lee, Ya-Li
    Fang, Steven
    Wei, Jiao
    Hui, Ai-Min
    CANCERS, 2022, 14 (20)
12345